Interesting international study below [1].
"Intake frequency patterns of total alcohol were similar for non-PCa men and PCa patients after adjusting for demographic and other factors.
"However, PCa patients were more likely to drink wine (light/moderate, OR = 1.11 ...) and spirits (light/moderate, OR = 1.14 ... and heavy, OR = 1.34 ...) than non-PCa men.
"Patients with aggressive PCa drank more beer than patients with non-aggressive PCa (heavy, OR = 1.48 ...).
"Interestingly, heavy wine intake was inversely associated with PCa aggressiveness (OR = 0.56 ...)." {That's the choice I made years ago.}
-Patrick
[1] pubmed.ncbi.nlm.nih.gov/354...
Cancers (Basel)
. 2022 Apr 14;14(8):1981. doi: 10.3390/cancers14081981.
Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status
Hui-Yi Lin 1 , Tung-Sung Tseng 2 , Xinnan Wang 1 , Zhide Fang 1 , Arnold H Zea 3 4 , Liang Wang 5 , Julio Pow-Sang 6 , Catherine M Tangen 7 , Phyllis J Goodman 7 , Alicja Wolk 8 , Niclas Håkansson 9 , Manolis Kogevinas 10 11 12 13 , Javier Llorca 13 14 , Hermann Brenner 15 16 17 , Ben Schöttker 15 , Jose Esteban Castelao 18 , Manuela Gago-Dominguez 19 20 , Marija Gamulin 21 22 , Davor Lessel 23 , Frank Claessens 24 , Steven Joniau 25 , The Practical Consortium 26 , Jong Y Park 27
Affiliations collapse
Affiliations
1 Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
2 Behavioral and Community Health Sciences Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
3 Department of Microbiology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
4 Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
5 Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
6 Department of Genitourinary Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
7 SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
8 Department of Surgical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.
9 Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
10 Barcelona Institute of Global Health (ISGlobal), 08036 Barcelona, Spain.
11 IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
12 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
13 CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
14 University of Cantabria, 39005 Santander, Spain.
15 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany.
16 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany.
17 Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
18 Genetic Oncology Unit, CHUVI Hospital, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), 36204 Vigo, Spain.
19 Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitariode Santiago, Servicio Galego de Saúde, SERGAS, 15706 Santiago de Compostela, Spain.
20 Department of Family Medicine and Public Health, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA.
21 Department of Oncology, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia.
22 School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia.
23 Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany.
24 Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Campus Gasthuisberg, University of Leuven, Herestraat 49, P.O. Box 901, 3000 Leuven, Belgium.
25 Department of Urology, University Hospitals Leuven, Herestraat 49, P.O. Box 7003 41, 3000 Leuven, Belgium.
26 The Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome Consortium, Sutton SM2 5NG, UK.
27 Department of Cancer Epidemiology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
PMID: 35454886 DOI: 10.3390/cancers14081981
Abstract
Background: Previous studies have shown that different alcoholic beverage types impact prostate cancer (PCa) clinical outcomes differently. However, intake patterns of specific alcoholic beverages for PCa status are understudied. The study's objective is to evaluate intake patterns of total alcohol and the three types of beverage (beer, wine, and spirits) by the PCa risk and aggressiveness status.
Method: This is a cross-sectional study using 10,029 men (4676 non-PCa men and 5353 PCa patients) with European ancestry from the PCa consortium. Associations between PCa status and alcohol intake patterns (infrequent, light/moderate, and heavy) were tested using multinomial logistic regressions.
Results: Intake frequency patterns of total alcohol were similar for non-PCa men and PCa patients after adjusting for demographic and other factors. However, PCa patients were more likely to drink wine (light/moderate, OR = 1.11, p = 0.018) and spirits (light/moderate, OR = 1.14, p = 0.003; and heavy, OR = 1.34, p = 0.04) than non-PCa men. Patients with aggressive PCa drank more beer than patients with non-aggressive PCa (heavy, OR = 1.48, p = 0.013). Interestingly, heavy wine intake was inversely associated with PCa aggressiveness (OR = 0.56, p = 0.009).
Conclusions: The intake patterns of some alcoholic beverage types differed by PCa status. Our findings can provide valuable information for developing custom alcohol interventions for PCa patients.
Keywords: aggressiveness; alcohol; beverage; prostate cancer.
JorgeW - Prostate Cancer
Advanced Prostate Cancer with Covid.
Supplements for metastatic prostate cancer 
